Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

Sponsor
Beijing Hospital
Study ID
NCT03950141
Phase
PHASE2
Status
Unknown

Conditions

  • HER-2 Negatived Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib and S-1 — DRUG
    Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC

Study Details

Apatinib is a novel drug which was produced by Jiangsu Hengrui Medicine Co.Ltd in China. It is approved in advanced gastric cancer（GC）. The investigators just want to design such kind of trail to prove its effect when combined with S-1 as maintenance in advanced HER-2 negatived GC treated with 4 cycles chemotherapy and valued as SD. Investigators will evaluate progression free survival (PFS) and overall survival (OS).

Key Dates

Start date
Jul 1, 2017
Status verified
May 2019
Primary completion
Jul 1, 2019
Completion
Jul 1, 2020

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib and S1 group
    Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC

Primary Outcome Measure

progression-free survival [ Time Frame: Patients will be followed for an average period of 1 year ]

Central Contacts